12 September 1997
Porcine islet xenotransplantation utilizing a vascularized bioartificial pancreas
Takashi Maki, Anthony P MonacoAnn Transplant 1997; 2(3): 69-71 :: ID: 497264
Abstract
Successful pancreas/islet transplantation restores normal glucose metabolism in patients with insulin dependent diabetes mellitus (IDDM) but requires chronic immunosuppression which is associated with morbidity and mortality. Immune exclusion devices containing pancreatic islets (bioartificial pancreas) are designed to provide glycemic control without immunosuppression. The immune exclusion is achieved by separating islets from the host by semipermeable membranes. Small molecules such as glucose, insulin and nutrients pass through, whereas immune lymphocytes and immunoglobulins are excluded by the membrane and unable to cause destruction of the islets. Use of xenogeneic islets (I.e., porcine islets) in the device also circumvents the shortage of human donor organs. This report provides a brief summary of our experience with vascularized bioartificial pancreas (VBAP) containing allogeneic and xenogeneic islets for treatment of experimental diabetes in dogs and describes our plans for a clinical trial of the VBAP in patients with IDDM.
Keywords: immune exclusion device, bioartificial pancreas
In Press
Original article
Biopsychosocial Effects of Donor Traits on Heart Transplant RecipientsAnn Transplant In Press; DOI:
Clinical Research
Ten-Year Retrospective Analysis of Continuous Renal Replacement Therapy in Burn Patients: Impact on Surviva...Ann Transplant In Press; DOI:
Original article
Factors Influencing Stress Disorders in Intensive Care Unit (ICU) Patients After Liver Transplantation: A C...Ann Transplant In Press; DOI: 10.12659/AOT.944320
Original article
Hepatopulmonary Syndrome and Liver Transplantation: Impact on Survival and Postoperative ComplicationsAnn Transplant In Press; DOI: 10.12659/AOT.945297
Most Viewed Current Articles
05 Apr 2022 : Original article 13,115
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 10,262
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
12 Jan 2022 : Original article 9,616
Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...DOI :10.12659/AOT.934738
Ann Transplant 2022; 27:e934738
15 Mar 2022 : Case report 7,277
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860